Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 15 IN PLASTIC CONTAINER versus AMINOSYN II 3 5 M IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 15 IN PLASTIC CONTAINER versus AMINOSYN II 3 5 M IN DEXTROSE 5 IN PLASTIC CONTAINER.
AMINOSYN II 15% IN PLASTIC CONTAINER vs AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids for protein synthesis, serving as substrates for nitrogen balance and tissue repair.
Aminogen II 3.5% M in Dextrose 5% provides essential and non-essential amino acids and dextrose for parenteral nutrition. Amino acids are utilized for protein synthesis and metabolic processes. Dextrose provides a source of calories and energy.
Intravenous infusion: 1.0 to 2.0 g amino acids/kg/day, maximum 125 mL/hour (3 g amino acids/kg/day).
Aminosin II 3.5% M in Dextrose 5% is administered intravenously. Typical adult dose is 1-2 L per day, providing 35-70 g amino acids and 50-100 g dextrose per day, infused at a rate of 0.5-1.5 mL/kg/hour.
None Documented
None Documented
Amino acids: rapid clearance, half-life 0.5-2 hours depending on individual and metabolic state. Clinical context: continuous infusion maintains steady state.
Amino acids have variable elimination half-lives (e.g., 0.5-6 h) depending on individual amino acid; dextrose half-life ~1-2 h. Clinical context: Used for continuous infusion, not bolus.
Renal: amino acids are filtered and reabsorbed; excess nitrogen is excreted as urea in urine. <5% fecal.
Amino acids are primarily metabolized, with nitrogen excreted as urea (renal, ~80-90%) and ammonia; minimal fecal excretion. Dextrose is fully metabolized to CO2 and water.
Category C
Category C
Amino Acid Solution
Amino Acid Solution